Eikon Therapeutics (EIKN) Investor presentation summary

Company overview and leadership

• Late-stage clinical biopharmaceutical company with a focus on integrating science and engineering for breakthrough therapeutics.

• Led by an experienced executive team and board with backgrounds from major pharma and biotech firms.

• Proprietary technology platform centered on single-molecule tracking (SMT) and advanced machine learning.

Pipeline and clinical programs

• Pipeline includes EIK1001 (TLR7/8 dual-agonist), EIK1003 and EIK1004 (PARP1 inhibitors), EIK1005 (WRN inhibitor), and EIK1006 (AR antagonist), targeting oncology and neurodegeneration.

• Multiple programs in Phase 1/2/3 trials, addressing melanoma, NSCLC, ovarian, breast, prostate, pancreatic, and MSI-high tumors.

• Additional discovery research ongoing in oncology and neurodegeneration.

EIK1001 (TLR7/8 dual-agonist) clinical progress

• Demonstrated activation of both innate and adaptive immunity, with monotherapy activity in Phase 1 and promising results in combination with pembrolizumab and chemotherapy.

• TeLuRide-005 Phase 2 NSCLC study showed ORR of 63.1% and DCR of 90.8% across all subtypes, with median duration of response >11 months.

• Safety profile generally consistent with standard of care, with no treatment-related deaths or high-grade cytokine release syndrome.

• Multiple ongoing and planned trials in NSCLC and melanoma, with key data readouts and interim analyses expected in 2026-2027.